# Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients

Study · id `cardio:ct-nct01351636` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01351636](<https://clinicaltrials.gov/study/NCT01351636>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01351636

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

## Technical summary

Registry record NCT01351636. Randomized; no masking; primary purpose treatment. Start 2011-04 (actual); primary completion 2018-10-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 300 participants (enrolled count; ClinicalTrials.gov record NCT01351636, source copy `cardio:ctgov-nct01351636-2019-04-17`, retrieved 2026-10-26)
- Started: 2011-04 (actual) (ClinicalTrials.gov record NCT01351636, source copy `cardio:ctgov-nct01351636-2019-04-17`, retrieved 2026-10-26)
- Primary completion: 2018-10-10 (actual) (ClinicalTrials.gov record NCT01351636, source copy `cardio:ctgov-nct01351636-2019-04-17`, retrieved 2026-10-26)
- Completion: 2018-10-10 (actual) (ClinicalTrials.gov record NCT01351636, source copy `cardio:ctgov-nct01351636-2019-04-17`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01351636, source copy `cardio:ctgov-nct01351636-2019-04-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01351636-2019-04-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients
- Acronym: AHOCEP
- Condition: Chronic Kidney Disease
- Intervention (Drug): Arotinolol Hydrochloride
- Intervention (Drug): Non arotinolol group
- Lead sponsor: Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Marubeni Pharmaceuticals (Suzhou) Co., Ltd. (`cardio:org-marubeni-pharmaceuticals-suzhou-co-ltd`)

## Provenance

Content hash: ad173f3e87fe98a4c63754b02b845057e34c83ac193fe220ad2ffac3c612fdcb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
